Who are Anlotinib hydrochloride capsule + TQB2450 injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Anlotinib and TQB2450 solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anlotinib-hydrochloride-capsule-tqb2450-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Anlotinib hydrochloride capsule + TQB2450 injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anlotinib hydrochloride capsule + TQB2450 injection (Anlotinib hydrochloride capsule + TQB2450 injection) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-target tyrosine kinase inhibitor + PD-L1 inhibitor combination. Area: Oncology.

phase 3 Multi-target tyrosine kinase inhibitor + PD-L1 inhibitor combination VEGFR, FGFR, PDGFR, c-Kit (anlotinib); PD-L1 (TQB2450) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Anlotinib hydrochloride capsule + TQB2450 injection (Anlotinib hydrochloride capsule + TQB2450 injection) — Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Anlotinib is a multi-target tyrosine kinase inhibitor combined with TQB2450, a PD-L1 inhibitor, to block tumor angiogenesis and enhance anti-tumor immune response.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anlotinib hydrochloride capsule + TQB2450 injection TARGET	Anlotinib hydrochloride capsule + TQB2450 injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Multi-target tyrosine kinase inhibitor + PD-L1 inhibitor combination	VEGFR, FGFR, PDGFR, c-Kit (anlotinib); PD-L1 (TQB2450)
Anlotinib and TQB2450 solution	Anlotinib and TQB2450 solution	Chinese PLA General Hospital	phase 3	Multi-target tyrosine kinase inhibitor + PD-L1 inhibitor combination	VEGFR, FGFR, RET, c-KIT (anlotinib); PD-L1 (TQB2450)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-target tyrosine kinase inhibitor + PD-L1 inhibitor combination class)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Chinese PLA General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anlotinib hydrochloride capsule + TQB2450 injection — Competitive Intelligence Brief. https://druglandscape.com/ci/anlotinib-hydrochloride-capsule-tqb2450-injection. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab